Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 225, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2021.113783
Keywords
Alzheimer's disease; Multifunctional agents; beta-amyloid; Tau protein; Cholinesterase inhibitors; 5-HT6 antagonists
Categories
Funding
- National Science Centre Poland [2016/23/D/NZ7/01328]
- Slovenian Research Agency - ARRS [P1-0208, L18157]
Ask authors/readers for more resources
The study identified compounds 17 and 35 as potential treatments for Alzheimer's disease, acting as 5-HT6R antagonists and cholinesterase inhibitors with different mechanisms of enzyme inhibition. In vitro experiments demonstrated their pharmacological characteristics and metabolic stability.
Multifunctional ligands as an essential variant of polypharmacology are promising candidates for the treatment of multi-factorial diseases like Alzheimer's disease. Based on clinical evidence and following the paradigm of multifunctional ligands we have rationally designed and synthesized a series of compounds targeting processes involved in the development of the disease. The biological evaluation led to the discovery of two compounds with favorable pharmacological characteristics and ADMET profile. Compounds 17 and 35 are 5-HT6R antagonists (K-i = 13 nM and K-i = 15 nM respectively) and cholinesterase inhibitors with distinct mechanisms of enzyme inhibition. Compound 17, a tacrine derivative is a reversible inhibitor of acetyl- and butyrylcholinesterase (IC50 = 8 nM and IC50 = 24 nM respectively), while compound 35 with rivastigmine-derived phenyl N-ethyl-N-methylcarbamate fragment is a selective, pseudo-irreversible inhibitor of butyrylcholinesterase (IC50 = 455 nM). Both compounds inhibit aggregation of amyloid beta in vitro (75% for compound 17 and 68% for 35 at 10 mu M) moreover, compound 35 is a potent tau aggregation inhibitor in cellulo (79%). In ADMET in vitro studies both compounds showed acceptable metabolic stability on mouse liver microsomes (28% and 60% for compound 17 and 35 respectively), no or little effect on CYP3A4 and 2D6 up to a concentration of 10 mM and lack of toxicity on HepG2 cell line (IC50 values of 80 and 21 mu M, for 17 and 35 respectively). Based on the pharmacological characteristics and favorable pharmacokinetic properties, we propose compounds 17 and 35 as an excellent starting point for further optimization and in-depth biological studies. (C) 2021 The Authors. Published by Elsevier Masson SAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available